undamentalytics Newsletter
Sign in

Dare Bioscience, Inc. cash flow statement

In fiscal 2025, Dare Bioscience, Inc.'s operations generated −$9.9m of cash; it spent $385,278 on capital projects, leaving free cash flow of −$10.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142016Dec 20162021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−21−17−19−0−29−18−395−10−11
Depreciation and amortisation0000000022
Stock-based pay1110223212
Capital spending0001001100
Free cash flow−21−17−19−1−29−18−395−10−12
Free cash flow after stock pay−22−17−20−1−30−20−423−12−13
Shares issued0001161—021—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DARE vs RNACABSI vs DAREDARE vs LGVNDARE vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dare Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dare Bioscience, Inc.